Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Oct 13, 2018 in Colorectal cancer | 0 comments

In a nutshell

This study investigated the effectiveness of cetuximab (Erbitux) combined with FOLFOX-4 (leucovorin, fluorouracil, and oxaliplatin) chemotherapy to treat metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that this treatment is associated with improved cancer outcomes.

Some background

Colorectal cancer is the second most common cancer. New therapies have been improving the outcomes of mCRC over the past decade. The combination of targeted therapies (treatments that target specific molecules on cancer cells and kill tumors) such as cetuximab with chemotherapy increases the effect of the treatment in these patients. However, the effectiveness of cetuximab plus the chemotherapy FOLFOX-4 in mCRC patients is still not clear.

Methods & findings

This study included information about 393 patients with mCRC. Patients underwent therapy with either FOLFOX-4 chemotherapy alone (200 patients) or FOLFOX-4 with cetuximab (193 patients). Progression-free survival (PFS; time from treatment to cancer progression), overall survival and overall response rates were measured.

Compared to chemotherapy alone, patients in the combination group had a 31% higher chance of a better PFS. These patients also had a 24% higher chance of a better overall survival. Moreover, patients in the combination group were 2.41 times more likely to have a better tumor response than with chemotherapy alone.

Serious side effects were reported in 19.1% of patients in the combination group and in 13.1% of those treated with chemotherapy alone. The most common side effects were a low white blood cell count and skin reactions. 

The bottom line

This study showed that patients with mCRC treated with cetuximab plus FOLFOX-4 have improved outcomes when compared to FOLFOX-4 alone.

The fine print

This study was funded by Merck KGaA, the manufacturer of cetuximab.

Published By :

Journal of clinical oncology

Date :

Sep 10, 2018

Original Title :

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial.

click here to get personalized updates